Loading stock data…
AARD
$5.46+0.03 (+0.55%)
Market ClosedLast close May 1
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aardvark Therapeutics, Inc. in the Healthcare sector is trading at $5.46. The stock is currently near its 52-week low of $3.35, remaining 48.4% below its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why AARD maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.46
Potential Upside
5%
Whystock Fair Value$5.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$16.90+209.5%
Range$6.00 – $45.00
Fundamentals
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$120.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.44%
Volume
Today's trading volume
82,256
Recent News
Discover 3 Promising Penny Stocks With Market Caps Over $100M
Over the last 7 days, the United States market has dropped 29%, and in the past year, it is down 82%, though earnings are forecast to grow by 16% annually. Despite these challenging conditions, identifying stocks with solid financials can still offer potential for growth. Penny stocks, often associated with smaller or newer companies, continue to present opportunities for investors seeking hidden value in quality companies. We've selected three examples that combine balance sheet strength...
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
Aardvark Therapeutics, Inc. (NASDAQ:AARD) is one of the penny stocks with potential to rise 1000 percent. Aardvark Therapeutics said on March 23, 2026, that it had voluntarily paused its Phase 3 HERO and open-label extension trials of ARD-101 in Prader-Willi syndrome, as well as the ARD-201 obesity program, while it works with the FDA on […]
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial
Aardvark Therapeutics (AARD) has drawn investor attention after voluntarily pausing its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, following reversible cardiac observations at higher than target doses. See our latest analysis for Aardvark Therapeutics. The voluntary HERO trial pause and related analyst downgrades have coincided with sharp weakness in Aardvark Therapeutics’ share price, with a 7 day share price return of 54.44% and a year to date share price return of 57.24%,...
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions
Aardvark Therapeutics recently paused its Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome after reversible cardiac-related observations emerged at above-target doses in a healthy volunteer study, delaying previously expected topline data timelines. The pause comes despite ARD-101 holding both Orphan Drug and Rare Pediatric Disease designations from the FDA for Prader-Willi Syndrome, underscoring the program’s regulatory importance and complexity. With the Phase 3 HERO trial on hold...
Why Aardvark Therapeutics Just Lost More Than Half Its Value
Biotech stock Aardvark Therapeutics crashed Monday after the company voluntarily stopped its Prader-Willi study.